https://scholars.lib.ntu.edu.tw/handle/123456789/528791
標題: | In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: Results from SMART (Study for Monitoring Antimicrobial Resistance Trends) | 作者: | Bochicchio G.V. Baquero F. PO-REN HSUEH Paterson D.L. Rossi F. Snyder T.A. Mccarroll K. Satishchandran V. Dinubile M.J. Chow J.W. |
公開日期: | 2006 | 卷: | 7 | 期: | 6 | 起(迄)頁: | 537-545 | 來源出版物: | Surgical Infections | 摘要: | Background: Since 2002, the worldwide Study for Monitoring Antimicrobial Resistance Trends (SMART) has tracked resistance patterns among aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections. Escherichia coli has been by far the most frequently isolated species. Methods: Antimicrobial susceptibilities for consecutive non-duplicate isolates of aerobic and facultative gram-negative bacilli recovered from intra-abdominal infections were determined by standard broth microdilution techniques. A subanalysis was performed for E. coli isolates from the first three years of the study. Results: A total of 7,002 E. coli isolates were recovered, most commonly from the peritoneal cavity followed by the biliary tract. Susceptibility rates to the 12 antimicrobial agents tested differed among geographic regions, with isolates from Asia/Pacific generally having the high-est resistance rates. Overall, extended-spectrum beta-lactamase (ESBL)-producers had a more antibiotic-resistant profile than non-ESBL-producers but usually were susceptible to the carbapenems and amikacin. Community-acquired E. coli strains comprised slightly more than one-half of the isolates and were susceptible to the agents tested more frequently than were hospital-acquired E. coli. Conclusions: The prevalence of antimicrobial resistance among E. coli isolated from intraabdominal infections is not inconsequential, especially in the Asia/Pacific region. The carbapenems and amikacin were consistently active in vitro against E. coli isolates worldwide, including ESBL-producers. ? Mary Ann Liebert, Inc. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528791 | ISSN: | 1096-2964 | DOI: | 10.1089/sur.2006.7.537 | SDG/關鍵字: | amikacin; antiinfective agent; beta lactamase; carbapenem derivative; cefepime; cefoxitin; ceftazidime; ceftriaxone; cilastatin plus imipenem; ciprofloxacin; clavulanic acid; ertapenem; levofloxacin; meropenem; piperacillin plus tazobactam; sultamicillin; tobramycin; abdominal infection; antibiotic sensitivity; article; bacterium isolation; drug sensitivity; Escherichia coli; geographic distribution; human; in vitro study; major clinical study; minimum inhibitory concentration; priority journal; Anti-Bacterial Agents; Biliary Tract; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; Microbial Sensitivity Tests; Peritoneal Cavity; Population Surveillance; World Health |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。